Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

ARTL 01.13.2025

Full Press ReleaseSEC FilingsOur ARTL Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
  • 12.09.2024 - Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
  • 11.18.2024 - Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Recent Filings

  • 12.23.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.20.2024 - 8-K Current report
  • 11.12.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com